Guanabenz Acetate
Based on 4 publication(s) in Google Scholar
Guanabenz (Acetate) (BR-750) is an alpha-2 selective adrenergic agonist used as an antihypertensive agent.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 98.93%
- No. CAS: 23256-50-0
- Fòrmula: C10H12Cl2N4O2
- Peso molecular:291.13
-
Almacenamiento:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications Citing Use of MedChemExpress (MCE) Guanabenz Acetate
MoreVer todos los productos específicos de isoformas Adrenergic Receptor
More
Actividad biológica
Alpha-2 Adrenergic Receptor[1].
Chemical Information
-
No. CAS 23256-50-0
-
Appearance Solid
-
Peso molecular 291.13
-
Fòrmula C10H12Cl2N4O2
-
Color Light yellow to yellow
-
SMILES
ClC1=C(/C=N/NC(N)=N)C(Cl)=CC=C1.CC(O)=O
-
Synonyms
BR-750; Wy8678 acetate
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Nature
2023 Sep;621(7977):188-195. PMID: 37648854 -
Cancer Lett
Repurposing the Neurokinin-1 receptor antagonist Aprepitant to eradicate relapsed/refractory acute lymphoblastic leukemia via mitochondria-driven necroptosis. [Abstract]2026 May 24:218621. PMID: 42184918 -
Cell Rep
2019 Dec 3;29(10):2929-2935.e4. PMID: 31801060 -
Brain Res Bull
The neuroprotective effect of guanabenz combined with α-lipoic acid in the hSOD1-G93A amyotrophic lateral sclerosis model. [Abstract]2026 Jun 1:239:111890. PMID: 41991114
Solvente y solubilidad
DMSO : ≥ 51 mg/mL (175.18 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 2.5 mg/mL (8.59 mM; ultrasonic and warming and heat to 60°C)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.59 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.59 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (275 KB)
-
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Korean - KR (479 KB)
- Portuguese - PT (479 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Walker, B.R., L.E. Hare, and M.W. Deitch, Comparative antihypertensive effects of guanabenz and clonidine. J Int Med Res, 1982. 10(1): p. 6-14. [Content Brief]
[2]. Bonham, A.C., et al., Studies on the mechanism of the central antihypertensive effect of guanabenz and clonidine. J Hypertens Suppl, 1984. 2(3): p. S543-6. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 3.4349 mL | 17.1745 mL | 34.3489 mL | 85.8723 mL |
| 5 mM | 0.6870 mL | 3.4349 mL | 6.8698 mL | 17.1745 mL | |
| DMSO | 10 mM | 0.3435 mL | 1.7174 mL | 3.4349 mL | 8.5872 mL |
| 15 mM | 0.2290 mL | 1.1450 mL | 2.2899 mL | 5.7248 mL | |
| 20 mM | 0.1717 mL | 0.8587 mL | 1.7174 mL | 4.2936 mL | |
| 25 mM | 0.1374 mL | 0.6870 mL | 1.3740 mL | 3.4349 mL | |
| 30 mM | 0.1145 mL | 0.5725 mL | 1.1450 mL | 2.8624 mL | |
| 40 mM | 0.0859 mL | 0.4294 mL | 0.8587 mL | 2.1468 mL | |
| 50 mM | 0.0687 mL | 0.3435 mL | 0.6870 mL | 1.7174 mL | |
| 60 mM | 0.0572 mL | 0.2862 mL | 0.5725 mL | 1.4312 mL | |
| 80 mM | 0.0429 mL | 0.2147 mL | 0.4294 mL | 1.0734 mL | |
| 100 mM | 0.0343 mL | 0.1717 mL | 0.3435 mL | 0.8587 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.